journal
MENU ▼
Read by QxMD icon Read
search

Clinical Journal of the American Society of Nephrology: CJASN

journal
https://www.readbyqxmd.com/read/30442869/home-based-care-for-ckd-for-high-risk-populations
#1
EDITORIAL
Wendy Rodgers
No abstract text is available yet for this article.
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442868/adrenocorticotropic-hormone-for-childhood-nephrotic-syndrome-the-atlantis-randomized-trial
#2
Chia-Shi Wang, Curtis Travers, Courtney McCracken, Traci Leong, Rasheed Gbadegesin, Alejandro Quiroga, Mark R Benfield, Guillermo Hidalgo, Tarak Srivastava, Megan Lo, Ora Yadin, Robert Mathias, Carlos E Araya, Myda Khalid, Alvaro Orjuela, Joshua Zaritsky, Samhar Al-Akash, Margret Kamel, Larry A Greenbaum
BACKGROUND AND OBJECTIVES: There is renewed interest in adrenocorticotropic hormone (ACTH) for the treatment of nephrotic syndrome. We evaluated the efficacy and safety of ACTH in children with frequently relapsing or steroid-dependent nephrotic syndrome in a randomized trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment...
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442867/association-of-monoclonal-gammopathy-with-progression-to-eskd-among-us-veterans
#3
Nicholas Burwick, Scott V Adams, Jeffrey A Todd-Stenberg, Nilka Rios Burrows, Meda E Pavkov, Ann M O'Hare
BACKGROUND AND OBJECTIVES: Whether patients with monoclonal protein are at a higher risk for progression of kidney disease is not known. The goal of this study was to measure the association of monoclonal protein with progression to ESKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a retrospective cohort study of 2,156,317 patients who underwent serum creatinine testing between October 1, 2000 and September 30, 2001 at a Department of Veterans Affairs medical center, among whom 21,898 had paraprotein testing within 1 year before or after cohort entry...
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442866/sleep-quality-and-sleep-duration-with-ckd-are-associated-with-progression-to-eskd
#4
Ryohei Yamamoto, Maki Shinzawa, Yoshitaka Isaka, Etsuko Yamakoshi, Enyu Imai, Yasuo Ohashi, Akira Hishida
BACKGROUND AND OBJECTIVES: Shorter or longer sleep duration and poor sleep quality are risk factors for numerous cardio-metabolic diseases, cardiovascular disease, and mortality in subjects with normal kidney function. The association of sleep duration and sleep quality with health outcomes in patients with CKD remains uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 4-year prospective cohort study in 17 nephrology centers in Japan, the CKD Japan Cohort (CKD-JAC) Study, assessed an association of self-reported sleep duration and sleep quality, on the basis of the Pittsburgh Sleep Quality Index (PSQI) questionnaire, with incidence of ESKD in 1601 patients with eGFR 10-59 ml/min per 1...
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442865/novel-models-for-health-care-delivery-for-ckd-for-disadvantaged-populations
#5
EDITORIAL
Joseph Lunyera, Clarissa Jonas Diamantidis
No abstract text is available yet for this article.
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442864/home-based-kidney-care-patient-activation-and-risk-factors-for-ckd-progression-in-zuni-indians-a-randomized-controlled-clinical-trial
#6
Robert G Nelson, V Shane Pankratz, Donica M Ghahate, Jeanette Bobelu, Thomas Faber, Vallabh O Shah
BACKGROUND AND OBJECTIVES: The burden of CKD is greater in ethnic and racial minorities and persons living in rural communities, where access to care is limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 12-month clinical trial was performed in 98 rural adult Zuni Indians with CKD to examine the efficacy of a home-based kidney care program. Participants were randomized by household to receive usual care or home-based care. After initial lifestyle coaching, the intervention group received frequent additional reinforcement by community health representatives about adherence to medicines, diet and exercise, self-monitoring, and coping strategies for living with stress...
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442863/monoclonal-gammopathies-and-kidney-disease-searching-for-significance
#7
EDITORIAL
Christina Hao Wang, Jonathan J Hogan
No abstract text is available yet for this article.
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30442862/does-what-goes-around-always-come-around
#8
EDITORIAL
Howard Trachtman
No abstract text is available yet for this article.
November 15, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30429153/addressing-disparities-in-living-donor-kidney-transplantation-a-call-to-action
#9
Krista L Lentine, Didier Mandelbrot
No abstract text is available yet for this article.
November 14, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30425104/pth-fgf23-and-intensive-blood-pressure-lowering-in-chronic-kidney-disease-participants-in-sprint
#10
Charles Ginsberg, Timothy E Craven, Michel B Chonchol, Alfred K Cheung, Mark J Sarnak, Walter T Ambrosius, Anthony A Killeen, Kalani L Raphael, Udayan Y Bhatt, Jing Chen, Glenn M Chertow, Barry I Freedman, Suzanne Oparil, Vasilios Papademetriou, Barry M Wall, Clinton B Wright, Joachim H Ix, Michael G Shlipak
BACKGROUND AND OBJECTIVES: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that intensive BP lowering reduced the risk of cardiovascular disease, but increased eGFR decline. Serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23) concentrations are elevated in CKD and are associated with cardiovascular disease. We evaluated whether intact PTH or intact FGF23 concentrations modify the effects of intensive BP control on cardiovascular events, heart failure, and all-cause mortality in SPRINT participants with CKD...
November 13, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30425103/clinical-pharmacology-of-antihypertensive-therapy-for-the-treatment-of-hypertension-in-chronic-kidney-disease
#11
Arjun D Sinha, Rajiv Agarwal
CKD is common and frequently complicated with hypertension both predialysis and in ESKD. As a major modifiable risk factor for cardiovascular disease in this high-risk population, treatment of hypertension in CKD is important. We review the mechanisms and indications for the major classes of antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β -adrenergic blocking agents, dihydropyridine calcium channel blockers, thiazide diuretics, loop diuretics, mineralocorticoid receptor blockers, direct vasodilators, and centrally acting α -agonists...
November 13, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30413403/correction
#12
(no author information available yet)
No abstract text is available yet for this article.
November 9, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30409899/prevalence-of-opioid-gabapentinoid-and-nsaid-use-in-patients-with-ckd
#13
Tessa K Novick, Aditya Surapaneni, Jung-Im Shin, Shoshana H Ballew, G Caleb Alexander, Lesley A Inker, Alex R Chang, Morgan E Grams
No abstract text is available yet for this article.
November 8, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30401735/intravenous-fluids-finding-the-right-balance
#14
Paul M Palevsky
No abstract text is available yet for this article.
November 6, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30397028/treatment-of-drug-induced-acute-tubulointerstitial-nephritis-the-search-for-better-evidence
#15
EDITORIAL
Dennis G Moledina, Mark A Perazella
No abstract text is available yet for this article.
November 5, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30397027/duration-of-treatment-with-corticosteroids-and-recovery-of-kidney-function-in-acute-interstitial-nephritis
#16
Gema Fernandez-Juarez, Javier Villacorta Perez, Fernando Caravaca-Fontán, Luis Quintana, Amir Shabaka, Eva Rodriguez, Liliana Gadola, Alberto de Lorenzo, Maria Angeles Cobo, Aniana Oliet, Milagros Sierra, Carmen Cobelo, Elena Iglesias, Miguel Blasco, Cristina Galeano, Alfredo Cordon, Jesus Oliva, Manuel Praga
BACKGROUND AND OBJECTIVES: Drug-induced acute interstitial nephritis represents an emerging cause of acute kidney disease, especially among polymedicated elderly patients. Although corticosteroids are frequently used, controversy exists about the timing of initiation, efficacy, safety, and duration of treatment. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective study of 182 patients with biopsy-proven drug-induced acute interstitial nephritis from 13 Spanish centers...
November 5, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30397026/fostering-innovation-in-symptom-management-among-hemodialysis-patients-paths-forward-for-insomnia-muscle-cramps-and-fatigue
#17
Jennifer E Flythe, Tandrea Hilliard, Elena Lumby, Graciela Castillo, Jazmine Orazi, Emaad M Abdel-Rahman, Amy Barton Pai, Matthew Bertrand Rivara, Wendy L St Peter, Steven Darrow Weisbord, Caroline M Wilkie, Rajnish Mehrotra
Individuals receiving in-center maintenance hemodialysis bear a high burden of both physical and mood symptoms. More than half of patients on hemodialysis report sleep disturbance, muscle cramps, and fatigue. Patients describe symptoms as having a deleterious effect on their quality of life, suggesting that symptom alleviation may meaningfully improve patient-reported outcomes. Moreover, patients on hemodialysis have identified symptom management as a key area for research and innovation, prioritizing symptom alleviation over other health outcomes such as mortality and biochemical indices...
November 5, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30385594/health-insurance-in-the-first-3-months-of-hemodialysis-and-early-vascular-access
#18
Eugene Lin, Matthew W Mell, Wolfgang C Winkelmayer, Kevin F Erickson
BACKGROUND AND OBJECTIVES: Patients without Medicare who develop ESKD in the United States become Medicare eligible by their fourth dialysis month. Patients without insurance may experience delays in obtaining arteriovenous fistulas or grafts before obtaining Medicare coverage. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective cohort study, we used a national registry to compare uninsured patients starting in-center hemodialysis with a central venous catheter between 2010 and 2013 with similar patients with Medicare or Medicaid...
November 1, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30381412/effects-of-the-potassium-binding-polymer-patiromer-on-markers-of-mineral-metabolism
#19
David A Bushinsky, David M Spiegel, Jinwei Yuan, Suzette Warren, Jeanene Fogli, Pablo E Pergola
BACKGROUND AND OBJECTIVES: Patiromer is a sodium-free, nonabsorbed, potassium-binding polymer that uses calcium as the counter-exchange ion and is approved for treatment of hyperkalemia. The 4-week TOURMALINE study in patients with hyperkalemia previously demonstrated that patiromer administered once daily reduces serum potassium similarly when given with or without food. We report a prespecified exploratory efficacy analysis as well as a post hoc efficacy and safety analysis of the TOURMALINE study on circulating markers of mineral metabolism...
October 31, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/30361338/the-kidney-accelerator-innovation-wanted-nephrologists-needed
#20
Suzanne Watnick
No abstract text is available yet for this article.
October 25, 2018: Clinical Journal of the American Society of Nephrology: CJASN
journal
journal
41332
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"